CG MED EQUIP.
838810
WANDA BEARING
920002
SUZHOUBEARING
430418
4
Guangdong Create Century Intelligent Equipment Group Corporation
300083
5
Hunan Creator Information Technologies
300730
US Stock MarketDetailed Quotes
PPBT Purple Biotech
- 2.940
- -0.120-3.92%
Close Feb 25 16:00 ET
- 2.940
- 0.0000.00%
Post 20:01 ET
7.59MMarket Cap-0.39P/E (TTM)
3.150High2.840Low13.72KVolume3.010Open3.060Pre Close40.32KTurnover0.55%Turnover RatioLossP/E (Static)2.58MShares20.60052wk High0.26P/B7.38MFloat Cap2.00052wk Low--Dividend TTM2.51MShs Float1390.000Historical High--Div YieldTTM10.13%Amplitude2.000Historical Low2.938Avg Price1Lot Size
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025
Purple Biotech Stock Forum
Revolutionary Cancer Drug NT219 Enters Phase 2 Trial Targeting $5B Market Opportunity
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Tuesday, 18th February at 7:00 am
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director of ...
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Thursday, 5th December at 7:13 am
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering o...
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
Tuesday, 3rd December at 8:23 am
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 472,...
📊⚡️📊
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
No comment yet